Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
P01.01 - HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC
00:00 - 00:00 | Presenter: Pasi A. Janne
- Abstract
Loading... -
+
P01.06 - CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase
00:00 - 00:00 | Presenter: Melissa L Johnson
- Abstract
Loading...
-
+
P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P77.02 - Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
00:00 - 00:00 | Presenter: Byoung Chul Cho
- Abstract
Loading...
-
+
OA03 - Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC
- 10:30 - 11:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
10:30 - 10:40 | Presenter: Alex I. Spira
- Abstract
Loading... -
+
OA03.04 - Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
10:40 - 10:50 | Presenter: Helena Yu
- Abstract
Loading...
-
+
ES14 - Novel Immunotherapy Strategies in NSCLC
- 11:45 - 12:45
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
ES14.02 - Cellular Therapies in NSCLC
11:45 - 11:57 | Presenter: Melissa L Johnson
- Abstract
Loading...
-
+
OA11 - A Symphony of Progress
- 15:30 - 16:30
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Small Cell Lung Cancer/NET
-
+
OA11.03 - A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
15:30 - 15:40 | Presenter: Taofeek K Owonikoko
- Abstract
Loading...
